Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Toradol

Toradol
In stock
10mg
from A$60.82
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$72.99A$60.82
A$2.03 per tablet

In brief

  • In Australia, toradol (ketorolac) is available in pharmacies as tablets and injectable formulations, but it is prescription-only (Rx) and should not be purchased without a valid prescription.
  • Toradol is used for short-term management of moderate to severe pain (especially post‑operative pain) and sometimes for aborting severe migraine; it is a non‑selective COX‑1 and COX‑2 inhibitor that reduces prostaglandin synthesis to provide potent analgesia.
  • Usual adult dose: oral 10 mg every 4–6 hours (commonly up to 40 mg/day); IM/IV 10–30 mg every 6 hours as needed; maximum treatment duration for oral/parenteral use is 5 days.
  • Forms of administration include oral tablets (typically 10 mg), intramuscular or intravenous injection (10 mg/mL and 30 mg/mL vials), with nasal spray and ophthalmic drops available in some markets.
  • Onset time: IV/IM within about 5–10 minutes, nasal around 10–15 minutes, oral typically 30–60 minutes.
  • Duration of action: analgesic effect generally lasts about 4–6 hours; overall therapy should not exceed 5 days due to safety risks.
  • Alcohol warning: avoid alcohol while taking toradol because it increases the risk of gastrointestinal bleeding and may worsen kidney toxicity and sedation.
  • The most common side effect is nausea.
  • Would you like to try toradol without a prescription?

Safety, Warnings And Patient Protection (Australia)

Basic Toradol Information

  • INN (International Nonproprietary Name): Ketorolac Tromethamine.
  • Brand Names Available In Australia: Toradol; ketorolac formulations (tablets and injectable vials).
  • ATC Code: M01AB15.
  • Forms & Dosages: Tablet 10 mg; injection 10 mg/mL and 30 mg/mL; eye drops 0.5% (Acular); nasal spray not widely marketed.
  • Manufacturers In Australia: Hoffmann-La Roche (original Toradol), Sandoz, Teva, Pfizer, Mylan, Normon and generic suppliers.
  • Registration Status In Australia: Widely registered with prescription-only status; check TGA database for sponsor details.
  • OTC / Rx Classification: Prescription-only (Rx).

Critical Overview For Patients And Prescribers

Are you worried this may be stronger than usual pain relief?

Ketorolac (Toradol) is a potent prescription-only NSAID used short-term for moderate to severe pain, particularly after surgery.

It works by inhibiting both COX-1 and COX-2 enzymes to reduce prostaglandin synthesis and give powerful analgesia.

Typical parenteral and oral regimens limit treatment to five days or less because of safety concerns.

Serious gastrointestinal bleeding and acute kidney injury are the principal risks that require upfront warnings to patients.

Allergic reactions including anaphylaxis and bronchospasm can occur in NSAID‑sensitive people and must be highlighted.

Advise patients to stop ketorolac immediately and seek urgent care for black stools or vomiting blood.

Advise patients to stop ketorolac immediately and seek urgent care for sudden breathlessness or severe rash.

Advise patients to stop ketorolac immediately and seek urgent care for new chest pain or markedly reduced urine output.

Before dispensing, document current medicines, over‑the‑counter analgesics, alcohol use and all allergies.

Use the checklist below as immediate red flags that demand action.

  • Immediate Red Flags To Action: black or tarry stools; vomiting blood; sudden shortness of breath; chest pain; severe blistering rash; very low urine output.
  • Prescriber Note: limit systemic ketorolac to ≤5 days and record stop date on the prescription and label.
  • Pharmacy Note: confirm no concurrent NSAID use and ensure patient understands bleeding and renal risks.

Patient Protection Procedures (Community And Hospital)

  • Verify identity, clinical indication and pregnancy or breastfeeding status before supply.
  • Check recent renal function for older adults and anyone with chronic kidney disease.
  • Ensure written instructions on maximum duration and the explicit advice to avoid other NSAIDs or anticoagulants concurrently.
  • Document counselling, allergies and medications in the patient record and notify the prescriber of any concerns.

High-Risk Groups (Elderly, Pregnancy, Chronic Illness)

Who should not take ketorolac or needs specialist review?

Elderly
Use lower doses (for example 10 mg) and reduce duration; monitor renal function, fluid and electrolyte status and fall risk.
Pregnancy And Breastfeeding
Avoid ketorolac in late pregnancy (third trimester) and seek specialist advice in breastfeeding; the drug is generally contraindicated in labour.
Active Peptic Ulcer Or Gastrointestinal Bleeding
Absolute contraindication; stop and refer if current ulcer or GI bleeding is present.
Severe Renal Impairment
Do not use; ketorolac is nephrotoxic and is contraindicated in renal failure or severe impairment.
NSAID Hypersensitivity
Avoid in known hypersensitivity to NSAIDs, history of asthma with NSAID sensitivity, angioedema or urticaria after NSAIDs.
Cardiovascular Disease / Hypertension
Require specialist review and monitoring due to increased cardiovascular risk and fluid retention potential.
Hepatic Impairment
Use with caution and consider dose reduction; monitor liver enzymes when clinically indicated.
Patients On Anticoagulants
Require careful review due to increased bleeding risk; coordinate with the prescriber and surgical teams.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Can this affect your ability to drive or work safely?

Ketorolac can cause dizziness, drowsiness and visual disturbance.

Advise patients not to drive or operate heavy machinery until they know how ketorolac affects them.

For safety-critical occupations such as truck drivers, heavy machinery operators and aviation personnel, follow employer policies and national workplace health guidance.

Encourage patients to report prescription use to their employer if required by workplace rules.

Document all safety counselling in the pharmacy record.

Q&A — “Can I Drive After Taking It In Australia?”

Q: Can I drive after receiving Toradol (ketorolac)?

A: Not until you know how it affects you.

If you experience drowsiness, dizziness or visual disturbance, do not drive.

This advice aligns with Australian road-safety and workplace guidance on prescription medicines that may impair concentration or alertness.

Usage Basics — INN, Brand Names & Legal Classification (Australia)

INN And Brands Available In Australia

What names might you see on a prescription or in hospital records?

The International Nonproprietary Name is ketorolac tromethamine.

Toradol and ketorolac product names are used internationally and appear in Australian listings as tablets and injectable vials.

Ancillary formulations in other countries include eye drops marketed as Acular and a nasal spray (Sprix) not widely marketed in Australia.

  • Examples Of Brands/Manufacturers Seen In Australia: Toradol (Roche), Sandoz generics, Teva generics, Pfizer generics, Mylan, Normon.
  • Common Pack Types: 10 mg tablets in blister packs and 10 mg/mL or 30 mg/mL ampoules or vials for injection.

Legal Classification (TGA Approval, PBS Context)

Is ketorolac prescription-only in Australia?

Yes — ketorolac is prescription-only (Rx) in Australia and products are registered with the Therapeutic Goods Administration (TGA).

Check the TGA database for current sponsor and product details before prescribing or dispensing.

PBS subsidy status varies by formulation and indication; verify the current PBS schedule for subsidy and listing details.

Note that ketorolac was withdrawn in Germany in 1993 because of gastrointestinal bleeding and kidney failure concerns; this historical point is useful when discussing risk.

Formulation Typical Availability In Australia PBS?
Tablet 10 mg Available at community pharmacies with a prescription Varies by product and indication; check PBS
Injection 10 mg/mL, 30 mg/mL Available in hospitals and some community settings; injectable supply varies Often hospital supplied; PBS listing varies
Eye Drops 0.5% (Acular) Available for ophthalmic use with prescription Check PBS for subsidised listings

Dosing Guide — Standard Regimens And Adjustments

Standard Regimens (Adult Dosing)

What is the usual adult dose and how long can it be used?

Route Typical Dose Max Duration
Oral 10 mg every 4–6 hours as needed ≤5 days
IM/IV 10–30 mg every 6 hours; some clinicians use a single 30 mg dose for migraine ≤5 days

Document the total daily dose and a clear stop date on the label and in the patient record.

Adjustments For Comorbidities And Special Populations

  • Elderly: use the lowest effective dose (for example 10 mg) and shorten duration; monitor renal function closely.
  • Renal Impairment: generally avoid ketorolac; high nephrotoxicity risk and dose reductions are often insufficient.
  • Children: rarely used; weight-based dosing under specialist supervision (for example 0.5–1 mg/kg IV/IM) if required.
  • Hepatic Impairment: use caution and consider dose reduction with monitoring of liver enzymes.

Q&A — “What If I Miss A Dose?”

Q: Missed ketorolac dose — what should I do?

A: Take the missed dose as soon as you remember unless the next scheduled dose is imminent.

Do not double up on doses to make up for a missed one.

If you are unsure, contact your pharmacist or prescriber for advice.

  • Counselling Checklist For Missed Dose And Monitoring: advise when to skip a dose, confirm maximum daily dose, reinforce the stop date and schedule renal checks for at‑risk patients.
  • Follow-Up: recommend a pharmacist or GP follow-up if pain control is inadequate or if adverse effects appear.

Interaction Chart — Food, Drinks And Common Drug Conflicts

Food And Drink Interactions (Alcohol, Australian Diet Context)

Does food change how ketorolac works?

There are no major food absorption interactions documented, but tablets can be taken with food to reduce gastric irritation.

Alcohol increases the risk of gastrointestinal bleeding with ketorolac and patients should minimise or avoid alcohol while on treatment.

Tailor counselling to cultural and regional factors; some communities have higher alcohol use and may need specific advice and support.

Common Drug Conflicts — High-Risk Combinations

Which medicines raise the risk when taken with ketorolac?

Concomitant Drug Interaction / Risk Action
Warfarin, DOACs Increased bleeding risk Avoid combination or closely monitor INR/bleeding; consult prescriber
Other NSAIDs / Aspirin Increased GI toxicity; no additive analgesic benefit Do not co‑prescribe; advise patient to stop OTC NSAIDs
Systemic Corticosteroids Higher risk of GI bleeding Use gastroprotection if clinically necessary and monitor
ACE Inhibitors / ARBs / Diuretics Possible renal function impairment and reduced antihypertensive effect Monitor renal function and blood pressure
SSRIs Increased bleeding risk due to platelet effects Advise monitoring and caution; discuss alternatives

Coordinate with anaesthetists and surgeons for peri‑operative patients because of bleeding risks with parenteral dosing.

Indications & Off-Label Uses In Australian Practice

TGA-Approved And Typical Indications (Short-Term)

Indication Typical Route Max Duration
Moderate–severe Acute Pain, including Post‑operative Pain Oral or IM/IV ≤5 days
Acute Migraine (Parenteral, Off‑Label) IM/IV single dose (30 mg used by some clinicians) Single dose; overall systemic use ≤5 days
Ophthalmic Inflammation (Eye Drops, Acular) Topical eye drops As directed for post‑op inflammation (days to weeks)

Systemic ketorolac should always be limited to five days or less due to safety concerns.

Off-Label And Pragmatic Uses (Hospital/Emergency)

  • Single 30 mg IM or IV dose is used in some emergency departments to abort acute migraine attacks.
  • Short parenteral courses are used for brief episodes of severe pain where opioids are undesirable or as part of multimodal analgesia.
  • Repeated dosing beyond recommended limits requires specialist approval and clear documentation of benefit versus risk.

Contraindications, Renal And Hepatic Precautions

Absolute Contraindications

  • Active peptic ulcer disease or current gastrointestinal bleeding — stop and refer.
  • Severe renal impairment or established renal failure — contraindicated.
  • Known hypersensitivity to NSAIDs, ketorolac, or previous NSAID-induced asthma, angioedema or urticaria.
  • Active bleeding, cerebrovascular bleeding or haemorrhagic diathesis.
  • Third‑trimester pregnancy and use during labour — contraindicated.
  • Breastfeeding without specialist advice — generally avoided.

Renal/Hepatic Monitoring And Dose Modification

What baseline tests and monitoring are required?

  • Obtain baseline renal function (serum creatinine or eGFR) for elderly patients and those with comorbidities before dispensing systemic ketorolac.
  • Monitor urine output and renal function if treatment continues or if symptoms suggest renal injury.
  • In hepatic impairment, use caution and consider monitoring liver function tests when clinically appropriate.
  • For polypharmacy and frail patients, coordinate with the prescriber to reassess choice of analgesic.

Side Effects, Adverse Events And Monitoring

Common (Mild–Moderate) Adverse Effects

  • Nausea and vomiting.
  • Dizziness and headache.
  • Indigestion, abdominal pain and dyspepsia.
  • Drowsiness and peripheral swelling.
  • Advise patients to report persistent gastrointestinal symptoms or a noticeable reduction in urine output.

Serious But Rare Adverse Events — Monitoring Priorities

Symptom Action
Black stools or vomiting blood Stop ketorolac and seek emergency care immediately.
Sudden breathlessness or wheeze Stop drug and seek urgent medical attention for possible bronchospasm or anaphylaxis.
Chest pain or neurological symptoms Stop drug and call emergency services for possible cardiovascular events or stroke.
Markedly reduced urine output Stop drug and arrange immediate assessment of renal function.

Overdose, Missed Dose, And Storage For Australian Households

Overdose Recognition And Urgent Actions

What to look for in an overdose and what to tell emergency staff.

Signs of overdose can include marked drowsiness, persistent nausea and vomiting, gastrointestinal bleeding and worsening kidney function.

If overdose is suspected, seek immediate emergency medical attention and bring the medicine packaging and prescription.

Ambulance transport is required for severe symptoms such as collapse, severe bleeding, seizures or loss of consciousness.

  • Checklist For ED Staff: medication name and strength, total quantity taken, time of ingestion, co‑medications, known allergies and baseline kidney function if available.
  • Treatment: supportive care and monitoring as there is no specific antidote.

Storage & Transport In Australian Climate

  • Store tablets and injectable vials at room temperature, ideally between 15–25°C.
  • Protect products from moisture and light and do not freeze injectable solutions.
  • For travel, keep medications in their original packaging with prescription documentation.
  • In hot or humid summer climates, advise cool, shaded storage at home and do not leave medications in cars.
Product Storage Temperature Handling Notes
Tablet 10 mg 15–25°C Blister packs keep tablets dry; store away from bathroom humidity.
Injectable Vials 10 mg/mL, 30 mg/mL 15–25°C Do not freeze; store in original sealed ampoules and protect from light.

Access & Purchase Options Across Australia

Major National Chains And Community Pharmacies

  • Ketorolac is prescription-only and dispensed through community pharmacies, including major chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart, and independent pharmacies.
  • Injectable forms are commonly supplied via hospitals and availability in the community varies.
  • Pharmacists can advise on formulation availability and liaise with prescribers for timely supply.

Online Pharmacies, Telehealth And E-Prescriptions

Can you order ketorolac online or via telehealth?

E‑prescriptions issued after a clinical assessment are acceptable for dispensing ketorolac from legitimate online pharmacies.

Remote and rural patients should be aware that injectable forms are hospital-managed and may not be available for courier delivery.

In our online pharmacy, toradol is available with a valid prescription, with discreet delivery to Australia in 9–21 days.

  • Checklist For Online Ordering: have a valid electronic or paper prescription, verify patient identity, confirm recent renal function where relevant and elect local pharmacist counselling.
  • Telehealth Tip: ask the telehealth clinician to document renal function and plan for follow-up if ketorolac is prescribed.

Price, PBS Subsidy And Rural Vs Urban Access Comparison

Pricing And PBS Considerations

Is ketorolac subsidised under the PBS?

PBS subsidy status varies by formulation and indication so always check the current PBS schedule before advising on cost.

If a product or indication is not listed on the PBS, patients pay the private prescription price and should compare community pharmacies for best price.

Concession cards and the PBS safety net can reduce out‑of‑pocket costs for eligible patients.

Source Typical Price Range PBS?
Community Pharmacy (Private Script) Varies by brand and pack size; check local pharmacy Depends on product and indication
Hospital Supply Usually hospital‑funded for inpatients Often provided through hospital formularies
Online Pharmacy (With Valid Rx) Compare private prescription prices across retailers Depends on PBS listing and dispensing pathway

Rural Versus Urban Access And Cultural Factors

  • Rural and remote patients may have limited access to injectable ketorolac and longer waits for GP appointments.
  • Telehealth can bridge some gaps but coordinate supply with a local clinic or pharmacy for monitoring and discharge information.
  • Cultural and financial sensitivities mean cost is often a key adherence factor in rural communities; suggest generic options where appropriate.
  • Provide contacts for local health services and Aboriginal and Torres Strait Islander health resources when relevant.

Alternatives Matrix — PBS-Listed Comparators And Pros/Cons

Common Therapeutic Alternatives (Comparative Points)

Drug Relative Potency Key Risks PBS Status
Ketorolac (Toradol) High analgesic potency GI bleeding, AKI, cardiovascular risk Prescription-only; PBS varies by formulation
Ibuprofen Moderate; available OTC GI upset, renal effects at high doses Often OTC; some prescriptions subsidised
Naproxen Moderate; longer duration GI and CV risks with longer use OTC and Rx options
Paracetamol Lower for severe pain but safer profile Hepatotoxicity in overdose OTC and widely used
Opioids High potency Dependence, sedation, respiratory depression Prescription-only; PBS varies
Triptans (Migraine) Migraine-specific Cardiovascular contraindications in some patients Prescription-only; PBS varies

Pros And Cons Checklist For Clinicians/Patients

  • Ketorolac: rapid, potent analgesia; limited to short courses and higher renal/GI risk.
  • Ibuprofen/Naproxen: safer for longer term use at appropriate doses; OTC choices simplify access.
  • Paracetamol: lower risk profile but may be less effective for severe postoperative pain.
  • Opioids: effective for severe pain but carry dependence and sedation risks.
  • Migraine Options: consider triptans or single-dose parenteral ketorolac as per local ED protocols.

Evidence, Clinical Findings And Updates (Australian & International 2022–2026)

What do recent studies and audits say about ketorolac use?

  • Parenteral ketorolac remains effective for short‑term moderate–severe postoperative pain and is used in ED settings for single‑dose migraine management in some protocols.
  • Surveillance and trials consistently show elevated risks of gastrointestinal bleeding and acute kidney injury with repeated or longer courses of ketorolac.
  • The mechanistic basis is non‑selective COX inhibition which explains both analgesic effects and prostaglandin‑mediated renal and GI adverse events.
  • Guidance trends emphasise limiting systemic use to five days or less and seeking alternatives for at‑risk populations.
  • Clinicians should consult recent TGA safety communications and local hospital audits for updates to local protocols.
Study Type Finding Clinical Implication
Systematic Reviews Short‑term parenteral ketorolac reduces pain scores effectively. Useful in acute settings but limit duration and monitor risk factors.
Pharmacovigilance Reports Increased reports of GI bleeding and AKI with repeated dosing. Enforce maximum 5‑day limit and avoid in renal impairment.
Local Hospital Audits Single‑dose 30 mg IM/IV shows benefit in ED migraine pathways. Consider as an option in selected patients with documented benefits and precautions.

Pharmacy Counselling Style & Patient Advice (PBS/National Guidance)

Practical Counselling Checklist For Australian Pharmacists

  • Confirm the indication, allergy history, pregnancy and breastfeeding status, renal disease and all current medications including OTC analgesics.
  • Explain the maximum systemic duration (≤5 days) and the importance of the stop date on the label.
  • Provide clear dosing schedule instructions and emphasise not to take other NSAIDs concurrently.
  • Discuss signs of serious adverse effects including GI bleeding and reduced urine output and when to seek urgent care.
  • Advise avoidance of alcohol while taking ketorolac to reduce bleeding risk.
  • Warn about possible dizziness or drowsiness and recommend not driving until the patient knows how the drug affects them.

Documentation And Follow-Up Actions

Record all counselling in the patient file and flag high‑risk patients for GP or renal monitoring.

Offer a pharmacist follow-up call within 24–72 hours for patients started on ketorolac in the community when clinically indicated.

When injectables are given in clinic or hospital, provide printed discharge guidance covering any subsequent oral dosing and monitoring requirements.

Handling, Cold-Chain And Pharmacy Storage Responsibilities

Household Storage In Australian Climate (Patient Guidance)

  • Store tablets and ampoules at 15–25°C, away from moisture and direct sunlight.
  • Do not freeze injectable solutions or store them in vehicles where temperatures can exceed safe ranges.
  • During hot summers, keep medication in a cool shaded cupboard or air‑conditioned room and check expiry dates before use.
  • Provide patients with a short storage checklist and a simple handout summarising safe home storage.

Cold-Chain And Pharmacy Handling (Professional)

Product Storage Temp Handling Notes
Tablet 10 mg 15–25°C Store in original blister; avoid bathroom humidity and long light exposure.
Injectable Vials 15–25°C Use validated insulated containers for distribution to rural clinics; maintain temperature logs during transport.

Pharmacies must follow TGA and GMP guidance for transport and storage and record batch numbers and expiry dates for traceability.

Delivery Across Australia

City Region Delivery time
Sydney New South Wales 9–14 days
Melbourne Victoria 9–14 days
Brisbane Queensland 9–14 days
Perth Western Australia 9–14 days
Adelaide South Australia 9–14 days
Canberra Australian Capital Territory 9–14 days
Hobart Tasmania 9–14 days
Darwin Northern Territory 9–14 days
Gold Coast Queensland 14–21 days
Newcastle New South Wales 14–21 days
Wollongong New South Wales 14–21 days
Geelong Victoria 14–21 days
Townsville Queensland 14–21 days
Cairns Queensland 14–21 days
Bendigo Victoria 14–21 days

Final Notes And Practical Examples

A common scenario in community practice is a Friday evening prescription for post-operative pain where the prescriber writes a five‑day course of ketorolac tablets.

In that case, the pharmacist should confirm baseline renal function if the patient is elderly or has comorbidities and explain the stop date and red‑flag symptoms.

Another example is a walk‑in clinic prescribing a single 30 mg IM dose for a severe migraine in the emergency setting where documentation of benefits, consent and follow-up advice are important.

For any supply, always cross‑check for anticoagulant use and recent NSAID exposure and document counselling in the file.

Related products